Partnering for success

Curve’s Microcycle platform can address a broad range of therapeutic targets beyond the company’s own pipeline and cancer focus.

Curve welcomes the opportunity to collaborate with pharma partners to identify novel hits and leads against their high-priority targets.

Curve’s 2022 five-target collaboration with MSD demonstrates the potential for Curve’s platform to address challenging disease targets.